Some professional investors look at the Dow industrials with a bit of suspicion since the largest companies by market value aren’t given the biggest weight in the index, as is the case for other benchmarks like the S&P 500 and Nasdaq composite.

The top five stocks by market cap in the 30-stock Dow are Nvidia, Apple, Microsoft, Amazon and Walmart. They would represent 69% of the index if it were market-cap weighted.

As it stands under the Dow’s methodology of giving more weight to higher priced stocks, the top five are Goldman Sachs, Caterpillar, Microsoft, Home Depot and Amgen. They make up about 35% of the index.

Home Depot has a weighting of about 4.7% in the blue-chip average, according to Dow Jones Market Data. If the Dow were sorted by market cap, its weighting would be only 1.7%.

This article was written by

Follow

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Following threats from the Food and Drug Administration (FDA) that it would take “decisive” action against companies selling “illegal copycat drugs,” telehealth company Hims & Hers announced it would pull the launch of its knockoff Wegovy weight loss drug.

“Since launching the compounded semaglutide pill on our platform, we’ve had constructive conversations with stakeholders across the industry,” Hims & Hers said on Saturday. “As a result, we have decided to stop offering access to this treatment.”

The FDA named checked Hims & Hers in its Friday announcement, saying, “These actions are aimed to safeguard consumers from drugs for which the FDA cannot verify quality, safety, or efficacy.  We take seriously any potential violations of the Federal Food, Drug, and Cosmetic Act.”

Hims & Hers’ decision also comes as Novo Nordisk threatened to take legal action over the cheaper version of its weight loss pill, which has not been approved by the FDA or gone through clinical trials.

NEW WEGOVY PILL OFFERS NEEDLE-FREE WEIGHT LOSS BUT MAY NOT WORK FOR EVERYONE

Hims & Hers Health, Inc., is featured outside the New York Stock Exchange, Jan. 21, 2021. (Reuters/Carlo Allegri / Reuters)

Hims & Hers announced Thursday that it would begin selling its compounded version of Novo’s Wegovy at an introductory price of $49 a month, which is around $100 less than the original, and the lowest price for a GLP-1 weight loss drug on the U.S. market.

Compounded drugs involve pharmacies mixing ingredients for certain specialized drugs at different dosages to make a copycat drug. The process has increased in the U.S. as Americans want lower-priced medications.

Shares of Novo first fell after the Hims announcement on Thursday, but then recovered and Hims’ shares fell after the FDA announcement on Friday.

PFIZER CEO ADDRESSES GROWING COMPETITION IN WEIGHT-LOSS DRUGS

Pharmaceutical company Novo Nordisk headquarters in Bagsvaerd, Copenhagen, Denmark. (Reuters/Tom Little/File Photo)

Hims didn’t say whether it planned to keep selling its compounded GLP-1 injection on its website.

CLICK HERE TO DOWNLOAD THE FOX NEWS APP

Novo and Hims previously had a partnership that allowed Hims to sell Wegovy, but Novo pulled out after accusing Hims marketing knockoff Wegovy drugs.

Hims’ CEO Andrew Dudum accused Novo of attempting to control how clinicians at Hims make decisions.

Reuters contributed to this report.